Floatz logo

Ivosidenib

Acute Myeloid Leukemia With Multilineage Dysplasia

Institut de Recherches Internationales ServierSmall moleculePhase 3Active
BB
66/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
52/ 100
Competitive Position
95/ 100

Competitive context

32 Active assets in the Acute Myeloid Leukemia With Multilineage Dysplasia cohort.

Asset / SponsorPhaseRating
CYTARABINE
National Cancer Institute (NCI)
Phase 3BB
ETOPOSIDE
Institut de Recherches Internationales Servier
Phase 2BB
Decitabine
National Cancer Institute (NCI)
Phase 3BB
Fludarabine
National Cancer Institute (NCI)
Phase 3BB
Cyclophosphamide
City of Hope Medical Center
Phase 3BB

View all 49 →

Same molecule, other indications

Ivosidenib is also rated in:

myeloproliferative neoplasmActive
B
Indicative · Phase 2
62 / 100
View asset →
acute myeloid leukemiaActive
B
Indicative · Phase 3
61 / 100
View asset →
chondrosarcomaActive
B
Indicative · Phase 2
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →